Editas Medicine has boosted its fundraising target in an forthcoming initial public offering to as much as $122.1 million, stating in a regulatory filing Monday that it plans to sell 6.78 million shares of stock at a range of $16 to $18 a share.
The Cambridge biotech, a leader in the emerging gene-editing approach known as CRISPR-Cas9, initially disclosed its plans to go public in a Jan. 4 filing with the Securities and Exchange Commission that said it would offer up to $100 million in stock, a placeholder sum.
Editas is expected to price its shares next week, according to the IPO calendar published by Greenwich, Conn., research firm Renaissance Capital.
